Particle Therapy Market Report and Forecast 2025-2034
Description
The global particle therapy market size was valued at USD 747.10 Million in 2024 , driven by increasing advancements and research studies to find better cancer treatment radiation therapies without damaging nearby tissues. The market size is anticipated to grow at a CAGR of 8.30% during the forecast period of 2025-2034 to achieve a value of USD 1658.30 Million by 2034 .
Particle Therapy: Introduction
Particle therapy, also known as particle beam therapy, is an advanced form of cancer treatment that uses charged particles such as protons or heavy ions to target and destroy cancer cells. Particle therapy delivers highly precise and controlled doses of radiation to tumours while minimizing damage to surrounding healthy tissues. Particle therapy is proven to show promising results in the treatment of certain cancers but it may not be considered for all types of cancer and patients.
Global Particle Therapy Market Analysis
The growth of the market is driven by increased research studies by scientists and doctors to provide better treatment options for cancer patients. For example, in a randomized clinical trial, researchers have discovered evidence promising shorter treatment time for breast cancer patients. In this trial, two separate dosing schedules of pencil-beam scanning proton therapy were compared. This therapy is known to be the most advanced type of proton therapy which is precise in targeting cancer cells without damaging healthy tissue resulting in reduced risk of side effects.
The particle therapy market demand is also driven by the increasing awareness among pharmaceutical companies that are looking to develop new and effective treatment therapy options for patients suffering from cancers and tumours all over the world. These companies are trying to develop proton therapies that are enabled with extreme precision when it comes to targeting cancer cells. For example, Terapet, a Geneva-based CERN start-up recently announced that they have ended up raising 2.3 million CHF (Swiss Francs) for the development of the next generation of nuclear imaging products. Terapet’s novel technology has the potential to make nuclear medicine imaging more accessible for every patient in the future. Terapet is targeted towards ensuring the right dose for every patient, every time. The company is also to exhibit its first product to the particle therapy community at PTCOG 2023 in Madrid.
The increased awareness and adoption of particle therapies are further escalating the global particle therapy market growth. For example, the inauguration of the much-awaited proton beam therapy facility in India took place earlier this year in Mumbai. This facility is the first in a public setup in the country. The government is set to provide this cutting-edge technology to 60% of the patients for free and the other 40% would pay a subsidized amount. The availability of such treatment options plays a huge role in reducing the mortality rate due to certain medical conditions such as cancer.
Additionally, Hitachi has successfully delivered a heavy ion therapy system to Taipei Veterans General Hospital situated in Taiwan and the system has also started operating as well. This is the first-ever heavy ion therapy system delivery made by Hitachi, outside of Japan.
Hitachi is committed to enhancing the quality of life for cancer patients in Taiwan and promoting patient-centered treatment. The company will persist in its efforts to expand the global reach of its particle therapy system business, thereby advancing the field of minimally invasive cancer treatments. Having successfully treated more than 85,000 patients to date, Hitachi offers a range of high-performance products and services. These offerings range from the specialized compact Proton single-room solution to the versatile Hybrid System, which combines the capabilities of proton and carbon therapy to provide even greater value.
Global Particle Therapy Market Segmentations
Global Particle Therapy Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Type
The global market is experiencing a significant rise in adoption, awareness, and demand. This rising awareness has led to a surge in clinical studies aimed at discovering the full potential of particle therapy for cancer and tumour treatment. Moreover, the increasing reliability of this treatment method, backed by positive outcomes, has further bolstered its popularity contributing to the global particle therapy market growth. According to data from the American Cancer Society, the United States is expected to witness over 1.9 million new cancer cases in 2023, with cancer ranking as the second leading cause of death and projected to account for approximately 609,820 deaths, equivalent to 1,670 lives lost each day.
Geographically, North America is currently leading the regional market, and this dominance is expected to persist throughout the forecast period. Factors contributing to regional market dominance include the presence of a well-established healthcare system, a growing geriatric population, and a rising number of healthcare facilities offering proton therapy favorable reimbursement policies.
Global Particle Therapy Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Particle Therapy: Introduction
Particle therapy, also known as particle beam therapy, is an advanced form of cancer treatment that uses charged particles such as protons or heavy ions to target and destroy cancer cells. Particle therapy delivers highly precise and controlled doses of radiation to tumours while minimizing damage to surrounding healthy tissues. Particle therapy is proven to show promising results in the treatment of certain cancers but it may not be considered for all types of cancer and patients.
Global Particle Therapy Market Analysis
The growth of the market is driven by increased research studies by scientists and doctors to provide better treatment options for cancer patients. For example, in a randomized clinical trial, researchers have discovered evidence promising shorter treatment time for breast cancer patients. In this trial, two separate dosing schedules of pencil-beam scanning proton therapy were compared. This therapy is known to be the most advanced type of proton therapy which is precise in targeting cancer cells without damaging healthy tissue resulting in reduced risk of side effects.
The particle therapy market demand is also driven by the increasing awareness among pharmaceutical companies that are looking to develop new and effective treatment therapy options for patients suffering from cancers and tumours all over the world. These companies are trying to develop proton therapies that are enabled with extreme precision when it comes to targeting cancer cells. For example, Terapet, a Geneva-based CERN start-up recently announced that they have ended up raising 2.3 million CHF (Swiss Francs) for the development of the next generation of nuclear imaging products. Terapet’s novel technology has the potential to make nuclear medicine imaging more accessible for every patient in the future. Terapet is targeted towards ensuring the right dose for every patient, every time. The company is also to exhibit its first product to the particle therapy community at PTCOG 2023 in Madrid.
The increased awareness and adoption of particle therapies are further escalating the global particle therapy market growth. For example, the inauguration of the much-awaited proton beam therapy facility in India took place earlier this year in Mumbai. This facility is the first in a public setup in the country. The government is set to provide this cutting-edge technology to 60% of the patients for free and the other 40% would pay a subsidized amount. The availability of such treatment options plays a huge role in reducing the mortality rate due to certain medical conditions such as cancer.
Additionally, Hitachi has successfully delivered a heavy ion therapy system to Taipei Veterans General Hospital situated in Taiwan and the system has also started operating as well. This is the first-ever heavy ion therapy system delivery made by Hitachi, outside of Japan.
Hitachi is committed to enhancing the quality of life for cancer patients in Taiwan and promoting patient-centered treatment. The company will persist in its efforts to expand the global reach of its particle therapy system business, thereby advancing the field of minimally invasive cancer treatments. Having successfully treated more than 85,000 patients to date, Hitachi offers a range of high-performance products and services. These offerings range from the specialized compact Proton single-room solution to the versatile Hybrid System, which combines the capabilities of proton and carbon therapy to provide even greater value.
Global Particle Therapy Market Segmentations
Global Particle Therapy Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Type
- Proton Therapy
- Heavy Ion Therapy
- Fast-Neutron Therapy
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Head and Neck Cancer
- Other Cancers
- Food and Beverage
- Nutraceuticals and Pharmaceuticals
- Cosmetics and Personal Care
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The global market is experiencing a significant rise in adoption, awareness, and demand. This rising awareness has led to a surge in clinical studies aimed at discovering the full potential of particle therapy for cancer and tumour treatment. Moreover, the increasing reliability of this treatment method, backed by positive outcomes, has further bolstered its popularity contributing to the global particle therapy market growth. According to data from the American Cancer Society, the United States is expected to witness over 1.9 million new cancer cases in 2023, with cancer ranking as the second leading cause of death and projected to account for approximately 609,820 deaths, equivalent to 1,670 lives lost each day.
Geographically, North America is currently leading the regional market, and this dominance is expected to persist throughout the forecast period. Factors contributing to regional market dominance include the presence of a well-established healthcare system, a growing geriatric population, and a rising number of healthcare facilities offering proton therapy favorable reimbursement policies.
Global Particle Therapy Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Advanced Oncotherapy
- IBA Worldwide
- Accuray Incorporated
- Brainlab
- Elekta AB
- Panacea
- Shinva Medical Instrument Co. Ltd
- xstrahl
- Danfysik A/S
- Hitachi Ltd.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Particle Therapy Market Overview
- 3.1 Global Particle Therapy Market Historical Value (2018-2024)
- 3.2 Global Particle Therapy Market Forecast Value (2025-2034)
- 4 Global Particle Therapy Market Landscape
- 4.1 Global Particle Therapy: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Particle Therapy: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Applications
- 5 Global Particle Therapy Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Particle Therapy Market Segmentation
- 6.1 Global Particle Therapy Market by Therapy Type
- 6.1.1 Market Overview
- 6.1.2 Proton Therapy
- 6.1.3 Heavy Ion Therapy
- 6.1.4 Fast-Neutron Therapy
- 6.2 Global Particle Therapy Market by Cancer Type
- 6.2.1 Market Overview
- 6.2.2 Prostate Cancer
- 6.2.3 Breast Cancer
- 6.2.4 Lung Cancer
- 6.2.5 Head and Neck Cancer
- 6.2.6 Other Cancers
- 6.3 Global Particle Therapy Market by Applications
- 6.3.1 Market Overview
- 6.3.2 Food and Beverage
- 6.3.3 Nutraceuticals and Pharmaceuticals
- 6.3.4 Cosmetics and Personal Care
- 6.4 Global Particle Therapy Market by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Particle Therapy Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Particle Therapy Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Particle Therapy Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Particle Therapy Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Particle Therapy Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Advanced Oncotherapy
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 IBA Worldwide
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Accuray Incorporated
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Brainlab
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Elekta AB
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Panacea
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Shinva Medical Instrument Co. Ltd
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 xstrahl
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Danfysik A/S
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Hitachi Ltd.
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
